Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study.
about
The mitochondria in diabetic heart failure: from pathogenesis to therapeutic promisePatient selection in heart failure with preserved ejection fraction clinical trialsClinical Phenotypes in Heart Failure With Preserved Ejection FractionAdvances in the pathophysiology and treatment of heart failure with preserved ejection fractionCardiovascular Late Effects and Exercise Treatment in Breast Cancer: Current Evidence and Future DirectionsEvidence for distinct effects of exercise in different cardiac hypertrophic disorders.Dual Endothelin-A/Endothelin-B Receptor Blockade and Cardiac Remodeling in Heart Failure With Preserved Ejection FractionCharacterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response.Combining patient proteomics and in vitro cardiomyocyte phenotype testing to identify potential mediators of heart failure with preserved ejection fraction.Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical ConsiderationsCardiovascular disease following hematopoietic stem cell transplantation: Pathogenesis, detection, and the cardioprotective role of aerobic trainingEffect of asymmetric dimethylarginine (ADMA) on heart failure development.Present Insights on Cardiomyopathy in Diabetic Patients.Accelerometer-Measured Daily Activity in Heart Failure With Preserved Ejection Fraction: Clinical Correlates and Association With Standard Heart Failure Severity Indices.Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes.Diabetic cardiomyopathy: An expression of stage B heart failure with preserved ejection fraction.Spironolactone for Management of Heart Failure with Preserved Ejection Fraction: Whither to After TOPCAT?Sudden cardiac death in heart failure with preserved ejection fraction: a target for therapy?The clinical dilemma of heart failure with preserved ejection fraction: an update on pathophysiology and management for physicians.Improved Diastolic Function Is Associated With Higher Cardiac Output in Patients With Heart Failure Irrespective of Left Ventricular Ejection Fraction.Metabolic support for the heart: complementary therapy for heart failure?Association of Impaired Glucose Regulation and Insulin Resistance With Cardiac Structure and Function: Results From ECHO-SOL (Echocardiographic Study of Latinos).Targeting Obesity and Diabetes to Treat Heart Failure with Preserved Ejection Fraction.Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology.Relationship of renal insufficiency and clinical features or comorbidities with clinical outcome in patients hospitalised for acute heart failure syndromes."Frailty, thy name is woman": syndrome of women with heart failure with preserved ejection fraction.Early-onset preeclampsia predisposes to preclinical diastolic left ventricular dysfunction in the fifth decade of life: An observational study.Associations and prognostic significance of diffuse myocardial fibrosis by cardiovascular magnetic resonance in heart failure with preserved ejection fraction
P2860
Q26829731-BCB3B83B-F019-4A0C-BD5C-F8E640F8BD1AQ27015845-DA605EF8-9235-4E22-BD4B-1DDF4F57436AQ28073079-F4C60EAD-703E-45C8-A511-862607BC8479Q33565707-E730DCE5-26C1-40A3-973A-0E2B84B97DCFQ33907581-8292BF4D-5E2F-45A5-9257-CBB74709E30EQ35117452-B9F11491-C242-4F6A-9B9A-A43B6E565D13Q36181771-7AE0BAB3-6774-4E1F-9B83-D0DE0E63BF7AQ36303452-C30950B1-8631-4EB3-B971-81BCC739382AQ36481310-8E3F902A-1A7C-410C-B6A0-6DBDEF20998DQ37011769-BE24C93E-151D-4376-A510-73ED220C24FAQ37213203-867FB5A4-4563-460D-A34D-01B81F80F172Q37245523-E4A98899-A2BD-4471-8C15-F2947E5541F2Q37402793-28C32AFD-5C54-4EE6-AB24-A5C5E78E3EBEQ38375946-7F0A4DD3-5829-4FBB-A59D-D50C8CE43961Q38427211-2B4CE234-0593-4A6F-9C12-6A4DCF2DCE6DQ38440130-BADBF125-5188-4CEF-927A-F3153429BFC4Q38593070-93FF339B-347D-4377-9B13-A0295D5BE142Q38695078-5BAF6973-DBE7-4F6D-B413-4B0E8EFEE988Q38768799-6EF965A0-4BF8-4495-86F4-B8048D7FE905Q38936829-14274DFD-A25A-4A11-A88A-419FF7DD24A5Q38998576-76EF2C7D-C086-4DF3-B50D-3EEF9E095DBCQ40546014-8B9ABD5A-E42D-43C4-9220-834AFE8BD5BDQ41025346-4A3D5DD2-10B6-4BB2-867F-79F54673ABDCQ47890686-A593E373-C499-4B66-8A43-F54103A2D0F8Q54601825-DD528ED5-EC7A-429F-8C6E-16066B3BB2C1Q55279096-0FDC40F2-EF84-4144-933E-A29B95315F3AQ55332174-0A3BE8C8-018A-4A46-8B38-DFAAEDD8C319Q58796332-9234E1A5-70AB-4E12-A8B3-B937B47C12FA
P2860
Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study.
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Cardiovascular phenotype in HF ...... a RELAX trial ancillary study.
@ast
Cardiovascular phenotype in HF ...... a RELAX trial ancillary study.
@en
Cardiovascular phenotype in HF ...... a RELAX trial ancillary study.
@nl
type
label
Cardiovascular phenotype in HF ...... a RELAX trial ancillary study.
@ast
Cardiovascular phenotype in HF ...... a RELAX trial ancillary study.
@en
Cardiovascular phenotype in HF ...... a RELAX trial ancillary study.
@nl
prefLabel
Cardiovascular phenotype in HF ...... a RELAX trial ancillary study.
@ast
Cardiovascular phenotype in HF ...... a RELAX trial ancillary study.
@en
Cardiovascular phenotype in HF ...... a RELAX trial ancillary study.
@nl
P2093
P2860
P50
P1476
Cardiovascular phenotype in HF ...... a RELAX trial ancillary study.
@en
P2093
Gregory D Lewis
Justin Vader
Marc J Semigran
Margaret M Redfield
Steven McNulty
Susan M Joseph
Victor G Dávila-Román
P2860
P304
P356
10.1016/J.JACC.2014.05.030
P407
P577
2014-08-01T00:00:00Z